Simpósio iBET - ITQB: “Protein Biopharmaceuticals at Bayer Healthcare”
O Instituto de Biologia Experimental e Tecnológica (iBET) e o Instituto de Tecnologia Química e Biológica (ITQB) realizam, dia 3 de julho, pelas 15h00, o simpósio “Protein Biopharmaceuticals at Bayer Healthcare”. A iniciativa decorrerá no auditório do ITQB-UNL, em Oeiras.
A participação é gratuita.
PROGRAMA:
15h00-15h45: “Expanding role of iBET to support discovery of Human Therapeutic Antibodies at Bayer”
Rene Hoet, vice president of Global Biologics
15h45-16h30: “Current Development in Antibody Drug Conjugates”
Heiner Apeler, director of Purification & Research Analytics
Break 30 min.
17h00-17h45: “Engineering of antibodies for successful development”, Dr. Lars Linden, Head of Protein Biochemistry
17h45-18h30: “Bringing Cell Line Development off the critical path of BMOL drug development”
Beate Müller-Tiemann, head of Cell and Protein Sciences of Global Biologics
Speakers Affiliation: Bayer Healthcare AG, Wuppertal/Köln – Germany
